Tysabri stories:
Biogen, Elan shares plummet on new Tysabri review
Oct 23rd, 2009 - Reuters
* European regulators to review risk, benefit of Tysabri * Review follows reports of 23 cases of PML worldwide * Shares of Biogen down 5.5 pct; Elan shares fall 20 pct (Updates share prices) BOSTON...
Europe Take Closer Look at Tysabri Dangers
Oct 23rd, 2009 - Wall Street Journal
A European panel has started a review of controversial multiple sclerosis drug Tysabri, sold by Biogen Idec Inc. and Elan Plc, citing a much higher rate of a rare brain infection than previously disclosed. In a statement...
FDA confirms 3 new infections linked to Tysabri
Sep 22nd, 2009 - Boston
NEW YORK—The Food and Drug Administration says it confirmed three new cases of a potentially lethal brain inflammation linked to the multiple sclerosis drug Tysabri.
Tysabri videos from YouTube:
8:27Multiple Sclerosis: Tysabri update
Update! I have a lot to update you on. I am loving Tysabri so far. Ijust had my second infusion. I have a lot going on in my life, as you will see. Never a dull moment, as every MS'er knows full well!
5:50Tysabri Recovery Series - New cases of PML
These are just my two-cents worth of thoughts regarding the new cases of PML.
2:43Tysabri Recovery Series - Three years on the drug
I've had my 36th Tysabri infusion a few days early
3:14Tysabri-A personal history
I have been diagnosed since 12/13/02 (not 05 like I said, an MS brain fart) and have been on Beta and copaxone in the past. I took Tysabri before it was taken off the market 2 years ago. These videos are of my many infussions to come. Started 10/6/06.
Tysabri from WikiPedia:
Natalizumab is a humanized monoclonal antibody against the cellular adhesion molecule ?4-integrin. Natalizumab is used in the treatment of multiple sclerosis and Crohn's disease. It is co-marketed by Biogen Idec and Élan as Tysabri, and was previously named Antegren. Natalizumab is administered by intravenous infusion every 28 days. The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers lining the intestines and blood-brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse, vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis, as well as increasing rates of remission and preventing relapse in Crohn's disease.
Read more on WikiPedia
